Welcome to Unearthing Diabetes Discoveries, your inside look at cutting-edge diabetes research. In this episode, I chat with Ulf Hannelius, CEO of Diamyd Medical, about their groundbreaking investigational immunotherapy that aims to safely and specifically slow down or halt the autoimmune destruction of insulin producing cells.  BIO: Meet Ulf Hannelius, the CEO of Diamyd Medical. With a PhD in Molecular Biology and an Executive MBA, Ulf brings over 15 years of expertise in the biotech industry, spanning diagnostics and drug development. He boasts a wealth of experience in steering complex development projects and has co-authored 12 peer-reviewed publications in the genetics field. LINKS: * Diagnode-3 Website * Diamyd Medical Website * Those interested in participating in the Diagnode-3 study who meet the criteria (diagnosed in the last 6 months and between 12 to 29 years old) will be screened for the specific genotype at their initial study visit. * Please help to spread the word because the study needs twice as many people to be screened to find the 50% of type 1’s with the HLA genotype. Thank you on behalf of Diamyd!